Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Mihoko Yamada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6362-2243; OpenAlex author ID A5071267798. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 5 papers · 2023: 5 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 18

  1. Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria. Co-author DOI 10.1007/s00595-025-03223-7↗
  2. Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1002/ags3.70052↗
  3. Clinical significance of resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis. Co-author DOI 10.1016/j.surg.2024.10.016↗
  4. Impact of Perioperative Hemoglobin A1c Levels on Survival Outcomes of Patients With Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1097/as9.0000000000000597↗
  5. Predictive factors of actual 5-y recurrence-free survival after upfront surgery for resectable pancreatic cancer: Exploration of patients who did not require n… Co-author DOI 10.1002/ags3.12834↗
  6. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
  7. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. Co-author DOI 10.1007/s00423-023-02906-4↗
  8. Corrigendum to Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer: [Surgery. 2022;172(6):1776-81, DOI: 10… Co-author DOI 10.1016/j.surg.2023.05.001↗
  9. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Co-author DOI 10.1038/s41598-023-31579-8↗
  10. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13564-7↗
  11. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Us… Co-author DOI 10.1245/s10434-023-13629-7↗
  12. Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1016/j.surg.2022.09.025↗
  13. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Co-author DOI 10.1245/s10434-022-11624-y↗
  14. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Co-author DOI 10.1245/s10434-022-11628-8↗
  15. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologic… Co-author DOI 10.1245/s10434-022-11639-5↗
  16. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Co-author DOI 10.1245/s10434-022-11662-6↗
  17. Clinical Implication of Node-negative Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09543-x↗
  18. Microscopic Venous Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6324-2↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teiichi Sugiura · 18 shared papers, 2018–2026 · strength 3.37
  2. Ryo Ashida · 18 shared papers, 2018–2026 · strength 3.37
  3. Katsuhiko Uesaka · 18 shared papers, 2018–2026 · strength 3.37
  4. Katsuhisa Ohgi · 17 shared papers, 2021–2026 · strength 3.29
  5. Yoshiyasu Kato · 4 shared papers, 2025–2026 · strength 1.06
  6. Yukiyasu Okamura · 6 shared papers, 2018–2024 · strength 0.89
  7. Hidemasa Kubo · 5 shared papers, 2022–2025 · strength 0.87
  8. Kentaro Yamazaki · 3 shared papers, 2022–2025 · strength 0.56
  9. Akiko Todaka · 3 shared papers, 2022–2023 · strength 0.50
  10. Yuji Shimizu · 2 shared papers, 2023 · strength 0.41
  11. Keiichi Ohshima · 2 shared papers, 2023–2024 · strength 0.34
  12. Kenichi Urakami · 2 shared papers, 2023–2024 · strength 0.34
  13. Taisuke Imamura · 2 shared papers, 2023–2024 · strength 0.34
  14. Tomoko Norose · 2 shared papers, 2022–2023 · strength 0.33
  15. Yuya Miura · 2 shared papers, 2022 · strength 0.30
  16. Jun Shibamoto · 1 shared paper, 2025 · strength 0.26
  17. Masao Uemura · 1 shared paper, 2024 · strength 0.22
  18. Takaaki Ito · 2 shared papers, 2018–2021 · strength 0.21
  19. Ken D Yamaguchi · 1 shared paper, 2024 · strength 0.18
  20. Ken Yamaguchi · 1 shared paper, 2023 · strength 0.16
  21. Masato Nagino · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.